REGENERON PHARMACEUTICALS INC

00-0000000

Form SC 13G/A November 10, 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) Regeneron Pharmaceuticals Inc. (Name of Issuer) Common stock (Title of Class of Securities) 75886F107 _____ (CUSIP Number) November 8, 2005 (Date of Event Which Required Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [] Rule 13d-1(b) [X] Rule 13d-1(c) [] Rule 13d-1(d) CUSIP No. 75886F107 13G/A Page 2 of 6 Pages 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON NOVARTIS PHARMA AG

2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a) _ (b) _
3	SEC USE ONLY			
4	CITIZENSHIP OR PLACE OF ORGANIZATION			
	SWITZERLAND			
			SOLE VOTING POWER 0	
BENEFICIALLY OWNED BY		6	SHARED VOTING POWER	
		7	SOLE DISPOSITIVE POWER	
PERSON WITH			SHARED DISPOSITIVE POWER 0	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0			
	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES _			1_1
	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
12	TYPE OF REPORTING PERSON			
	CO			

CUSIP No. 75886F107 13G/A Page 3 of 6 Pages

Item 1(a).
Name of Issuer:

Regeneron Pharmaceuticals Inc.

Item 1(b). Address of Issuer's Principal Executive Offices:

777 Old Saw Mill River Road Tarrytown, NY 10591-6707

Item 2(a). Name of Person Filing:

Novartis Pharma AG

Item 2(b). Address of Principal Business Office or, if none, Residence: Lichtstrasse 35 CH-4002, Basel Switzerland Item 2(c). Citizenship: Switzerland Item 2(d). Title of Class of Securities: Common stock Item 2(e). CUSIP Number: 75886F107 Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: (a) $|_|$ Broker or dealer registered under section 15 of the Act; (b) |_| Bank as defined in section 3(a)(6) of the Act; (c) |_| Insurance company as defined in section 3(a)(19) of the Act; (d) |_| Investment company registered under section 8 of the Investment Company Act of 1940; (e) |_| An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) |_| An employee benefit plan or endowment fund in

CUSIP No. 75886F107 -----

accordance with Rule 13d-1(b)(1)(ii)(F);

13G/A Page 3 of 6 Pages

(g) |_| A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G) (Note: See

Item 7);

- (h) $|_|$ A savings association as defined in section 3(b) of the Federal Deposit Insurance Act;
- (i) $\mid _ \mid$ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
- (j) |_| Group, in accordance with Rule 13d-1(b)(1)(ii)(H).

If this statement is filed pursuant to Rule 13d-1(c), check this box. |X|

Item 4. Ownership.

- (a) Amount beneficially owned: Zero.
- (b) Percent of class: Zero.
- (c) Number of shares as to which the person has:
 - (i) sole power to vote or to direct the vote: Zero.
 - (ii) shared power to vote or to direct the vote: Zero.
 - (iii) sole power to dispose or to direct the disposition of: ${\tt Zero.}$
 - (iv) shared power to dispose or to direct the disposition
 of: Zero.
- Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not Applicable.

CUSIP No. 75886F107 13G/A Page 3 of 6 Pages

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certification.

Not applicable.

CUSIP No. 75886F107

13G/A

Page 3 of 6 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, ${\tt I}$ certify that the information set forth in this statement is true, complete and correct.

Dated: November 10, 2005

NOVARTIS PHARMA AG

By: /s/ Joseph E. Mamie

Name: Joseph E. Mamie

Title: Head of Operational Treasury

By: /s/ Christina Ackermann

Name: Christina Ackermann

Title: Head of Legal General Medicine